TMO

The article questions whether Illumina shareholders should consider Thermo Fisher instead. No further details are provided.

Broyhill Asset Management, a Charlotte-based firm, issued its third-quarter 2026 investor letter. The letter can be downloaded here. The Broyhill Equity Composite decreased by 0.3% in Q3, underperforming the MSCI All Country World Index, which gained 1.7%. For the first nine months of the year, the Composite returned 1.9%, compared to 13.4% for the Index. The […]

Citigroup keeps a Buy rating on Thermo Fisher Scientific and lifts its target price to $800 from $685. The move reflects confidence in the company’s prospects.

201-Page Report Finds Library Preparation Leads and Long-Read Sequencing Grows Fastest as Clinical Oncology Testing and Genomics Programs Expand, While Fragmented Reimbursement and Lab Capacity Limits Slow AdoptionDublin, Oct.

A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most closely watched names.

Barclays maintains an Overweight rating on Thermo Fisher Scientific and raises its target price to $775 from $750. The update signals a positive outlook.

RBC Capital keeps a Sector Perform rating on Thermo Fisher Scientific and increases its target price to $730 from $580. This suggests a favorable view of the company.

TD Cowen keeps a Buy rating on Thermo Fisher Scientific and raises its target price to $810 from $760. The rating indicates strong support for the stock.